RESEARCH GRANT AWARDS
AWARDS LIST.
Totals by Year
2025 - $1,019,994
2024 - 1,139,000
2023 - $891,364
2022 - $1,199,966
2021 - $749,812
2020 - $630,000
2019 - $690,000
2018 - $750,000
2017 - $747,772
2016 - $720,000
2015 - $840,000
2014 - $810,000
2013 - $808,500
2012 - $720,000
2011 - $599,780
2010 - $438,000
2009 - $435,000
2008 - $619,993
2007 - $232,600
2006 - $384,551
Amounts flagged (*) below are funded by Cancer League of Colorado and a generous matching grant from MDC/Richmond American Homes Foundation
Todd Hankinson MD - CO-PI Siddhartha Mitra, PhD - CO-PI
Advancing next generation models for Craniopharyngioma
$60,000
2025
Heather Brechbuhl, PhD Jessica Finlay-Schultz, PhD
Targeting SDC2-Mediated Platelet-Tumor Cell Interactions to Block Breast Cancer Metastasis
$60,000
2025
Austin Gillen, PhD (Co-PI) James DeGregori, PhD, (Co-PI) Michael Alberti, MD, PhD (Co-PI)
Exploring the mechanisms underlying aging-dependent selection for hematopoietic malignancy associated mutations in U2AF1
$59,994
2025
Sheera Rosenbaum, PhD (PI-Fellow) Heide L. Ford, PhD (Mentor)
Elucidating Novel Mechanisms of NK Cell Suppression in metastatic breast cancer
$30,000
2025
Maria Cecilia Caino, PhD
Novel Roles of GCN2 in metastatic prostate cancer
$30,000
2025
Lynn Heasley, PhD Raphael Nemenoff, PhD
Defining the interplay of tumor heterogeneity and the immune microenvironment in determining targeted therapy responses of lung adenocarcinoma
$60,000
2025
Takamitsu Kato, PhD (PI)
CDK11 mutation and genomic instability and cancer predisposition
$30,000
2025
Joshua Thurman, MD (Co-PI) Gina Bouchard, PhD (Co-PI)
Immune Amplification to Target Lung Cancer
$60,000
2025
Joselyn Cruz Cruz, PhD (PI - Fellow) Michael R. Veneris, MD (Mentor)
TAM Receptor Inhibition to Enhance CAR-T Cell Therapy in Pediatric Sarcomas
$30,000
2025
Wenjuan Liao, PhD (PI-Fellow) Patricia Ernst, PhD (Mentor)
Defining the Distinct Biology and Therapeutic Vulnerabilities of Lineage-switched AML following CAR T Relapse
$30,000
2025
Jen Cimons, PhD (PI - Fellow) Michael R. Veneris, MD (Mentor)
JAKed Up for Tolerance: A Ruxolitinib-Based Strategy for Allogeneic CAR T Persistence
$30,000
2025
Laurel Hind, PhD (Co-PI) Richard Tobin, PhD (CoPI)
Uncovering the Role of MDSC-Driven Mitochondrial Transfer in Metabolic Shifts and Immunoresistance in Melanoma
$60,000
2025
Joseph L. Sottnik, PhD (Co-PI) Maria Jose Contreras-Zárate, PhD (Co-PI)
Exploring mechanisms of bone and brain metastases in lobular breast cancer
$60,000
2025
Maggie Musick PhD (PI - Fellow) Matthew J. Sikora, PhD (Mentor)
Defining Drivers of CDH1 loss-induced mammary lineage remodeling and oncogenesis
$30,000
2025
Michael Graner, PhD
Blocking chordoma invasion with phage peptides against chordoma cells and extracellular vesicles
$30,000
2025
Jeffrey Moore, PhD
“Precision tools for disrupting the cytoskeleton in metastatic cancer
$30,000
2025
Reema Wahdan-Alaswad, PhD Jennifer Richer, PhD
Thyroid Hormone and Androgen Receptor Cross-Talk Induces a Poor Prognosis in Estrogen Receptor-Positive Breast Cancer
$60,000
2025
Zhirui Wang, DVM, PhD (PI) Hatim Sabaawy, MD (Co-PI)
Bivalent CD47 Immunotoxin for Targeted Therapy of Lung Cancer
$60,000
2025
John Tentler, PhD
Summer Fellowship Program
$30,000
2025
Paul A. Roberson, PhD, (Co-PI) Andrea Bonetto, PhD (Co-PI)
Sestrin 1 attenuates muscle wasting in cancer cachexia
$60,000
2025
Vincent Chen, PhD (PI-Fellow); M. Eric Kohler, MD, PhD (Co-PI) Siddhartha Mitra, PhD (Mentor)
Targeting Glioblastoma with Augmented anti-B7H3 CARMacrophage Therapy in Immunocompetent Murine Models
$30,000
2025
Matthew Witkowski, Ph.D.(PI)
Dissecting long-chain fatty acid transport as a mechanism of acute lymphoblastic lukemia chemotherapy resistance
$30,000
2025
Kyle Concannon, MD (Co-PI) Peter Fettci MD, PhD (Co-PI)
Overcoming ALK TKI Resistance with EGFR-Targeting, BiTE-Secreting Car T Cell Therapy
$60,000
2025
John Tentler, PhD
Cancer Research Summer Fellowship Program
$30,000
2024
Mercedes Rincon, Ph.D. PI; Craig Jordan Ph.D. Co-PI
Overcoming AML Resistance to VEN-AZA by inhibiting Complex I Activity with MCJ Mimetics
$60,000
2024
Rebecca Schweppe, PhD
Targeting FAK and Ribosome Biogenesis in thyroid cancer
$30,000
2024
Benjamin Bitler, PhD
Overcoming Therapy Resistance via EHMT1/2 Targeting
$30,000
2024
Andrea Bonetto, PhD
PRPS1 is a new mediator of skeletal muscle atrophy in cancerinduced cachexia
$30,000
2024
Shi-Long Lu, MD, PhD Daniel Frank, PhD
Microbiota in the immunotherapy response of oral squamous cell carcinoma
$60,000
2024
Christine Walsh, MD
CU-GENES (CU Genetic Engagement, Education, Screening
$30,000
2024
Robin Dowell, D.Sc; Esteban J Rozen
PAK2 inhibition of Myc oncogenes as a novel therapeutic option for pediatric cancer.
$30,000
2024
James DeGregori, PhD; Jonathan Kurche, M.D., Ph.D
Mutation-driven Clonal expansions as both seed and soil in lung cancer initiation
$30,000
2024
Catherine Danis, PhD
Examining the metabolic fitness of the Adjunctive LATactivating CAR T cell against Acute Myeloid Leukemia
$30,000
2024
Allison J. L’Hotta, PhD, OTD
Fatigue Screening and Triage for the management of Pediatric cancer-related fatigue (FAST-PEDS)
$30,000
2024
Jung-Jae Lee, PhD
Precision Surgery in Head and Neck Cancer with advanced Chemiluminescent Nanoprobes
$30,000
2024
Charlotte Feddersen, MD, PhD, PI (Fellow);Adam Green, MD, (Mentor)
Combination XPO1 Inhibition and Cellular Immunotherapy for the Treatment of Pediatric High-Grade Gliomas
$30,000
2024
Sabrina L Spencer, PhD
Identification of kinase inhibitors that exhibit off-target activation of the Integrated Stress Response
$30,000
2024
Daniel LaBarbera, PhD, PI; Farnoush Banaei-Kashani, Ph D, Co-PI
AI-powered Drug Discovery focused on developing best-in Class KDM4 Inhibitors to advance Epigenetic therapy for Metastatic Colon Cancer
$60,000
2024
Joshua C Black, PhD; Heide Ford, PhD
Determining, Identifying and Controlling Copy Number of Mesenchymal Genes During Epithelial to Mesenchymal Transition in Breast Cancer
$30,000
2024
Joe Nassour, PhD
Investigating the telomere-mitochondria connection in age-associated tumorigenesis
$30,000
2024
Dinoop Ravindran Menon, PhD, CO-PI; Sharon R. Pine, PhD, CO-PI
Targeting OCT1 mediated adaptive resistance in K-RAS mutant LUAD
$60,000
2024
Kole DeGolier, Ph.D CO-PI Fellow;James Scott-Browne, Ph.D. CO-PI - Mentor; Terry Fry, M.D CO-PI
Single cell functional genomics to track transcriptional fate of CAR-T cell responses to leukemia
$60,000
2024
James Costello, PhD
Assessing the phenotypic effects of innervation in bladder cancer
$30,000
2024
Steven Dow, DVM, PhD (PI); Kathryn Wotman, DVM. (Co-PI);Lynn Pezzanite, DVM, PhD (Co-PI)
Equine Model of Penile Carcinoma for Evaluation of Immune Responses to Novel Intratumoral Immunotherapy
$29,999
2024
Neelanjan Mukherjee, PhD; Heide Ford, PhD
Defining and targeting stress-induced translational control as a means to inhibit metastasis
$60,000
2024
Carol Sartorius, PhD Heather Brechbuhl, PhD
Mechanisms and vulnerabilities of fatty acid metabolism in endocrine resistant breast cancer
$60,000
2024
Michael Alberti, MD, PhD
Dissecting the functional consequences of aberrant mRNA splicing by U2AF1(S34F) in hematologic malignancy
$30,000
2024
Laurent Gapin, PhD,
Enhancing T-Cell Therapy through PLZF Modulation
$30,000
2024
PI - Emily Blauel-Bocko, MD; Co-PI - Breelyn Wilky, MD
Elucidating exceptional responders to cabozantinib using a novel functional assay
$60,000
2024
Nathan A. Dahl, MD
Practical translation of proteosome inhibition for posterior-fossa ependymoma
$30,000
2024
Jean Mulcahy Levy, MD
Pre-clinical investigation to support IIT of CDK7 Inhibition in Pediatric Embryonal CNS tumors
$30,000
2024
Michael Verneris, MD
When CAR T Cells Fall Short: Leveraging CAR T Homing and Activation to Sensitize Tumors to Chemotherapy
$30,000
2024
Jay Hesselberth, PhD and Linda vanDyk, PhD
Immune Targeting therapies to disrupt virus-associated lymphomas
$60,000*
2023
Marisa R Moroney, MD
Assessing the HDAC2/MTA3 Complex as an Epigenetic Driver in Gynecologic Carcinosarcomas
$30,000
2023
Richard Blake Ross, MD
Enhancing Immune-Mediated Radiotherapy Efficacy in Murine models of Head and Neck Cancer through Peroxisome Proliferator-Activated Receptor Modulation
$30,000*
2023
Bethany Veo, PhD
Evaluating IDH1 facilitation of radiation resistance in MYC-amplified MB
$30,000
2023
Brad Haverkos, MD and Eduardo Davila, PhD
Leveraging Chemoimmunotherapy to improve treatments for newly diagnosed aggressive T-cell lymphomas
$60,000*
2023
Sujatha Venkataraman, PhD, Mark Eric Kohler, PhD and Rajeev Vibhakar, MD
Preclinical testing of gated CAR-T cells in overcoming tumor antigen escape for effective immunotherapy against DIPG
$60,000*
2023
Kaylyn Utley, M.B, B.Ch., BAO
Effect of p53 on CAR T cell efficacy against acute leukemia
$30,000
2023
Carlo Marchetti, PhD, Todd Pitts, PhD
To investigate the role of NLRP3 in Pancreatic Ductal Adenocarcinoma (PDAC)-associated chemotherapy tolerance
$60,000
2023
Masanori Hayashi, MD and Srinivas Ramachandran, PhD
Investigation of cell-free DNA to define EWG-FLI1 activity in Ewing Sarcoma
$60,000*
2023
Mayumi Fujita, MD, PhD and Dinoop Ravindran Menon, PhD
The role of H3k4me3 remodeling in melanoma BRAF/MEK inhibitor resistance
$60,000
2023
Quentin Vicens, PhD
Targeting the BMI1 oncogene mRNA using small molecules
$30,000
2023
Dong Wang, MS, PhD
Targeting CDK8 as a therapeutic approach for MYC driven medulloblastoma
$30,000
2023
Shi Biao Chia, PhD
Influenza virus infection in reawakening dormant metastatic breast tumor cells in the lung
$30,000
2023
Nathan A. Dahl, MD
Deconvoluting enhancer rewiring in giloma relapse following radiotherapy
$30,000*
2023
Peter Kabos, MD, Srinivas Ramachandran, PhD
Personalization of care for patients with advanced microsatellite stable colon cancer
$60,000
2023
Elena Shagisultanova, MD, PhD
Choosing the right target: comparing PIK3CA and AKT inhibition in HER2+PIK3CA-mutated breast cancer
$30,000
2023
John Tentler, PhD
Cancer Research Summer Fellowship Program
$30,000
2023
Katherine Lind, MD
A feasibility study of family interviews after early death in childhood cancer
$21,497
2023
Rui Zhao, PhD
Understanding and inhibiting the EYA3 and PP2A-B55a interaction in triple-negative breast cancer
$30,000
2023
Zhirui Wang, PhD, Rajeev Vibhakar, MD, PhD, Sujatha Venkataraman, PhD
Development of Novel Dual CD99/B7-H3 immunotoxins against DIPG, a fatal brain tumor in children
$60,000
2023
Rebecca Schweppe, PhD
The role of subcellular localization of FAK in thyroid cancer
$30,000
2023
Kristine Corkum, MD
Validation and Implementation of a pediatric Oncofertility Risk Calculator for Children Diagnosed with an Extracranial Solid Tumor
$29,867
2023
John Tentler, PhD
Cancer Research Summer Fellowship Program
$30,000
2022